S S Ziborova

Novokuznetsk City Clinical Hospital No. 1 named after G.P. Kurbatov, Novokuznetsk, Russia.

2 publications 2023 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does S S Ziborova research?

Dr. Ziborova studies the treatment of ischemic stroke, which occurs when a blood vessel supplying blood to the brain is blocked. This blockage can lead to serious health issues, including disabilities. She investigates how well the medication Revelise works for patients after experiencing a stroke. Her research specifically looks at patient outcomes over time, including their recovery and the impact on their quality of life.

Key findings

  • In the International PRIMA Study, nearly half (49.9%) of the 2,202 patients treated with Revelise had good outcomes at discharge.
  • After 90 days, this number rose to 66.4%, indicating improved recovery for stroke patients.
  • The study highlights that Revelise is effective in reducing disabilities associated with strokes, even among older patients and those with additional health issues.

Frequently asked questions

Does Dr. Ziborova study ischemic strokes?
Yes, Dr. Ziborova specializes in researching treatments for ischemic strokes.
What medication has Dr. Ziborova researched?
She has researched the effectiveness of Revelise (alteplase) for treating ischemic stroke.
Is Dr. Ziborova's work relevant to older stroke patients?
Yes, her research shows that Revelise benefits older patients and those with other health issues.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

[Local fibrinolisis in nontraumatic intraventricular hemorrhages].

2023

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Volkova AK, Polukarova EA, Ziborova SS, Borzikin SV, Kalinin AY

Plain English
This study looked at a new treatment method for patients experiencing bleeding in the brain, specifically those with intraventricular hemorrhage, which often leads to serious complications like hydrocephalus. They found that using a combination of external drainage and a medication to break down blood clots significantly improved outcomes for a 52-year-old patient, helping to manage her symptoms quickly and increase her chances of recovery. This approach could lower the risk of death and disability in similar cases of hemorrhagic stroke. Who this helps: This helps patients with brain bleeding and their healthcare providers.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.